Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
09:00am, Thursday, 20'th Feb 2025
Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
09:00am, Wednesday, 19'th Feb 2025
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializin
CNS Pharmaceuticals Announces Reverse Stock Split
08:30am, Wednesday, 19'th Feb 2025
HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
09:00am, Tuesday, 18'th Feb 2025
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
08:00am, Monday, 10'th Feb 2025
In-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
09:10am, Thursday, 05'th Dec 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average su
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first hal
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
09:10am, Friday, 15'th Nov 2024
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond da
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
09:15am, Monday, 04'th Nov 2024
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
09:00am, Friday, 01'st Nov 2024
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prim
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
02:50pm, Wednesday, 23'rd Oct 2024
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prim
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
09:00am, Thursday, 10'th Oct 2024
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
09:15am, Tuesday, 08'th Oct 2024
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
09:00am, Monday, 23'rd Sep 2024
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical
